VERDESO™ (DESONIDE) FOAM, 0.05%
Verdeso™ Foam is a petrolatum-based emulsion aerosol foam containing the active ingredient desonide, a low-potency topical corticosteroid.
Verdeso Foam is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.
Patients should be instructed to use Verdeso Foam for the minimum amount of time necessary to achieve the desired results because of the potential for Verdeso Foam to suppress the hypothalamic-pituitary-adrenal (HPA) axis (see Precautions). Treatment should not exceed 4 consecutive weeks.
Published Studies Related to Verdeso (Desonide Topical)
An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. [2009.11]
The treatment of seborrheic dermatitis includes topical antifungal agents to eradicate Malassezia spp, corticosteroids, which treat the inflammatory component of the disease and keratolytics which remove scale and crust. This study compared the efficacy of a nonsteroidal topical cream and a low-potency topical corticosteroid for the treatment of mild to moderate seborrheic dermatitis of the face in 77 volunteers randomized to twice-daily treatment with nonsteroidal cream or corticosteroid cream for up to 28 days...
Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. [2007.02]
Low to mid potency corticosteroids remain a cornerstone of therapy for atopic dermatitis (AD)...
Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences. [2005.03]
CONCLUSION: The presence of 0.05% desonide does not impair or improve the Malassezia susceptibility to 2% ketoconazole when growing on lipid-enriched human stratum corneum. Copyright 2005 S. Karger AG, Basel.
Overview on desonide 0.05%: a clinical safety profile. [2004.07]
Desonide (as a cream, ointment, or lotion formulation) is widely used for the treatment of steroid-responsive dermatoses... The excellent safety profile of desonide revealed by this pharmacovigilance program is supported by a review of published clinical trial results.
Efficacy, cutaneous tolerance and cosmetic acceptability of desonide 0.05% lotion (Desowen) versus vehicle in the short-term treatment of facial atopic or seborrhoeic dermatitis. [2002.08]
The differences between topical corticosteroids are based mainly on their potency, safety and patient acceptability. The aim of this study was to evaluate a mild- to mid-potent topical corticosteroid, desonide 0.05%, on these three parameters in an Australian cohort of patients with facial seborrhoeic or atopic dermatitis...
Clinical Trials Related to Verdeso (Desonide Topical)
Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis [Active, not recruiting]
The purpose of this research study is to better understand how this study drug works when
people use it to treat atopic dermatitis. Desonate has been approved by the US Food and Drug
Administration (FDA) for atopic dermatitis.
Efficacy Emollient on Xerosis in Children With Atopic Dermatitis [Recruiting]
Atopic dermatitis is a frequent, chronic inflammatory disease influenced by local,
immunological, genetic and environmental factors. Important symptoms of atopic dermatitis
are dry skin, intense pruritus and impaired epidermal barrier function. Atopic dermatitis is
associated with skin barrier dysfunction that facilitates an easier allergen penetration
into the skin with an increased irritation and subsequent cutaneous inflammation. A lack of
important stratum corneum intercellular lipids and an inadequate ratio between compounds
enhance trans-epidermal water loss leading to xerosis. Skin hydration by emollient therapy
usually twice daily improves dryness and subsequently pruritus during the treatment of
atopic dermatitis and especially improves the barrier function. Emollients make part of
basic therapy (grade 1) for treatment of atopic dermatitis (European Academy of Dermatology
and Venereology Task Force 2009 Position Paper). Improvement of cutaneous barrier
alteration, measured by skin hydration, is a key element for evaluation of emollient
The primary objective of this study is to demonstrate the efficacy of the tested product
(V0034CR01B) cream on xerosis in children with atopic dermatitis compared to the excipient
formula during 28 days.
Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis [Not yet recruiting]
This study compares the effectiveness of two topical creams for atopic dermatitis in
pediatric subjects. Subjects will be randomly assigned to use one of the two creams twice
daily for 6 weeks or until clear.